Request Appointment
300 East 66th StreetFloors 1 - 4New York, NY 10065
Overview of Dr. Jhaveri
Dr. Komal Jhaveri is an oncologist in New York, NY and is affiliated with Memorial Sloan Kettering Cancer Center. She received her medical degree from KJ Somaiya Medical College and has been in practice 16 years. Dr. Jhaveri accepts several types of health insurance, listed below. She is one of 506 doctors at Memorial Sloan Kettering Cancer Center who specialize in Oncology. She also speaks multiple languages, including Gujarati, Hindi, Marathi, and Urdu. She has more than 100 publications and over 500 citings.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2009 - 2012
KJ Somaiya Medical CollegeClass of 2001
Certifications & Licensure
FL State Medical License 2021 - Present
NY State Medical License 2009 - 2026
NJ State Medical License 2023 - 2025
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
- Conquer Cancer Foundation Young Investigator Award ASCO
Clinical Trials
- Chemotherapy With or Without Trastuzumab After Surgery in Treating Women With Invasive Breast Cancer Start of enrollment: 2011 Jan 06
- Toll-like Receptor (TLR) 7 Agonist, Cyclophosphamide, and Radiotherapy for Breast Cancer With Skin Metastases Start of enrollment: 2011 Aug 19
- A Study Evaluating Talazoparib (BMN 673), a PARP Inhibitor, in Advanced and/or Metastatic Breast Cancer Patients With BRCA Mutation (EMBRACA Study) Start of enrollment: 2013 Oct 14
- Join now to see all
Publications & Presentations
PubMed
- First-In-Human Phase 1/2a Study of the First-In-Class CDK2/4/6 Inhibitor PF-06873600 Alone or with Endocrine Therapy in Patients with Breast Cancer.Timothy A Yap, Jonathan W Goldman, Shaveta Vinayak, Antoaneta Tomova, Erika Hamilton
Clinical Cancer Research. 2025-04-17 - Inavolisib plus letrozole or fulvestrant in PIK3CA-mutated, hormone receptor-positive, HER2-negative advanced or metastatic breast cancer (GO39374): An open-label, mul...Philippe L Bedard, Komal L Jhaveri, Melissa K Accordino, Prof Andrés Cervantes, Valentina Gambardella
European Journal of Cancer. 2025-03-30 - 7 citationsImlunestrant with or without Abemaciclib in Advanced Breast Cancer.Komal L Jhaveri, Patrick Neven, Monica Lis Casalnuovo, Sung-Bae Kim, Eriko Tokunaga
The New England Journal of Medicine. 2025-03-27
Press Mentions
Well-Designed Phase Ia and Ib Trials Point the Way to New Treatment OptionsMarch 5th, 2025- 5-Minute Journal Club Issue 5 with Dr Komal Jhaveri: Reviewing the Role of Oral SERDs in the Management of ER-Positive Metastatic Breast CancerMarch 3rd, 2025
- Discoveries from MSK Research: Highlights and Innovations – February 13, 2025February 13th, 2025
- Join now to see all
Professional Memberships
- Amersican Soceity of Clinical OncologyMember
Other Languages
- Gujarati, Hindi, Marathi, Urdu
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
Multiplan PHCS PPOMultiplan PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
